Study of DT-216P2 in Healthy Adults
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests a single dose of a new medicine called DT-216P2 in healthy volunteers to see how safe it is and how the body handles it. It may help researchers learn more about the drug for future use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- You are in good health overall, with no major medical conditions.
- Your body mass index (BMI) is between 16 and 32, and you weigh no more than 100 kg (about 220 pounds).
- You agree to avoid very hard exercise during the study.
- You and your partner use approved birth control if there is a chance of pregnancy.
- You are willing to follow all study rules and give your written permission to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called DT-216P2 in people with Friedreich's ataxia. It aims to find the right dose and see how safe and tolerable it is.
This trial tests an injectable medicine called CTI-1601 for Friedreich's ataxia (FRDA). It is an open-label study, meaning everyone knows they are getting the drug. The study is for people who have taken CTI-1601 before (without serious side effects) or are new to the drug.
This study follows people with Friedreich's ataxia (FA) over time to learn more about the disease. It helps researchers understand how FA affects people of all ages and may lead to better treatments.
This study tests a drug called omaveloxolone (BIIB141) for children and teens with Friedreich’s Ataxia. It looks at how well the drug works and how safe it is over a longer time.
This study tests an investigational drug given as a daily injection to see if it can improve walking and balance in people with Friedreich's ataxia.
This trial tests a one-time gene therapy called LX2006 for heart problems caused by Friedreich ataxia. The goal is to see if it can improve heart function and structure.
Hear when a new Friedreich Ataxia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.